Calyxt, Inc. (CLXT) — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2022. The request metadata names Cibus, Inc., but the supplied filing is for Calyxt, Inc.; confirm the intended company before relying on this summary.
Business context
Calyxt describes itself as an early-stage plant-based synthetic biology company developing products and customer solutions using its PlantSpring technology platform and BioFactory production system. Cellectis owned 56.1% of Calyxt’s common stock at quarter-end.
Financial results and position
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | $0.032 million | $4.402 million |
| Gross profit (loss) | $0.032 million | $(2.343) million |
| R&D expense | $2.941 million | $3.050 million |
| SG&A expense | $3.180 million | $4.258 million |
| Operating loss | $(6.089) million | $(9.681) million |
| Net loss | $(5.619) million; $(0.13) per share | $(10.028) million; $(0.27) per share |
| Adjusted EBITDA loss (non-GAAP) | $(4.955) million | $(6.827) million |
| Operating cash used | $6.404 million | $9.417 million |
| Cash, cash equivalents and restricted cash | $17.883 million | $14.421 million at Dec. 31, 2021 |
| Total liabilities | $23.424 million | $23.062 million at Dec. 31, 2021 |
| Stockholders’ equity | $14.921 million | $14.132 million at Dec. 31, 2021 |
At March 31, cash and cash equivalents were $17.285 million; $0.598 million was restricted. Current liabilities were $9.520 million. Liabilities included $13.742 million of operating lease obligations, $0.379 million of financing lease obligations, and a $4.976 million liability for common warrants. The filing does not identify material conventional borrowing debt.
Material changes and unusual items
- Revenue fell 99% year over year, principally because Calyxt completed the wind-down of its soybean product line in late 2021. Q1 2022 revenue was associated with a customer-funded soybean development project for a potential palm-oil alternative.
- The lower net loss reflected the end of soybean product-line losses and lower operating expenses. The prior-year comparison also included a $2.5 million recapture of non-cash stock compensation from forfeited awards.
- The February follow-on offering generated approximately $10.0 million in net proceeds. It included 3.88 million common shares, 3.88 million pre-funded warrants, and 7.76 million common warrants.
- A $0.487 million non-operating gain arose from remeasuring common warrants at fair value as the stock price declined. The warrants are liability-classified and may require cash settlement under specified change-of-control conditions.
- Adoption of lease accounting in January 2022 brought operating lease assets and liabilities onto the balance sheet; the company recorded approximately $14.1 million of each at adoption. The accounting change did not affect operations or cash flows.
Outlook, risks and contingencies
- Management stated that existing cash, the offering proceeds and planned reassessment of discretionary spending were expected to fund operations into early 2023. Management nevertheless concluded that substantial doubt existed about the company’s ability to continue as a going concern, citing the need for additional capital to support its plans for 12 months or more from the filing date.
- The company expects continued losses for several years and said 2022 operating cash use and capital spending would exceed 2021 levels, driven by BioFactory scaling and AIML investment. Additional financing may be unavailable or dilutive; “baby shelf” rules may limit equity issuance while public float remains below $75 million.
- Management reported that the pilot BioFactory was operational and had completed multiple runs. The company reported a 35-fold yield increase from land-based production to lab-scale reactors and projected a possible aggregate increase of up to 130-fold at pilot scale; these are company-reported results and projections, not established commercial outcomes.
- Management targeted selecting two to four customer-demand compounds for development by year-end 2022 and pursuing technology and agricultural-trait licenses during 2022. A customer-funded palm-oil-alternative soybean project remained on track for completion in Q1 2024. These are targets and plans, not guaranteed results.
- Key risks include execution and scale-up of BioFactory production, customer demand and commercialization, access to capital, competition, intellectual-property challenges, supply-chain or facility disruptions, and uncertainty around AIML performance. The filing reported no material pending litigation and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the company identity: the supplied filing is Calyxt, Inc., not Cibus, Inc.
- Assess the going-concern warning, cash runway assumptions, expected cash burn, and the company’s ability to raise additional capital.
- Track whether BioFactory scale-up and the reported yield improvements are independently validated and translate into customer orders and revenue.
- Verify progress on the 2022 compound-selection and licensing targets and the customer-funded project timetable.
- Review potential dilution and warrant terms: on May 4, 2022, Calyxt received notice that all 3.88 million pre-funded warrants had been exercised; the filing reported 42,768,163 common shares outstanding on that date.